With Generous Partner Abbott Back For More, Reata Aims High Again
This article was originally published in Start Up
Executive Summary
Texas biotech Reata can add another $400 million license deal, its second with Abbott, to the $178 million it has raised from venture backers. But this time it's for preclinical assets.
You may also be interested in...
The Abbott Split Up: Who Wins?
After implementing a major workforce reduction in January, Abbott Laboratories re-organized its diversified company into three units – proprietary pharmaceuticals, durable growth products and innovation-driven devices. Its latest announcement cements that change: Abbott will divide into a diversified medical products company.
Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes
Further Phase II data show biomarker evidence, and Reata will now look to a 1,600-patient Phase III trial to prove the drug can lead to improved kidney function.
Reata Sets Sights On 2012 Bardoxolone Launch With $78 Million Financing In Hand
Funding will allow Reata to complete the second of two pivotal trials for its lead product candidate in development for advanced chronic kidney disease.